{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:07:03Z","timestamp":1782176823669,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The use of positron-emission tomography (PET)\/computed tomography (CT) in radiation therapy (RT) has increased. Radiation oncologists (RadOncs) have access to PET\/CT with a\u00a0variety of tracers for different tumor entities and use it for target volume definition. The German Society of Nuclear Medicine (DGN) and the German Society of Radiation Oncology (DEGRO) aimed to identify current patterns of care in order to improve interdisciplinary collaboration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We created an online survey on participating RadOncs\u2019 use of PET tracers for different tumor entities and how they affect RT indication, dose prescription, and target volume definition. Further topics were reimbursement of PET\/CT and organizational information (fixed timeslots and use of PET with an immobilization device [planning\/RT-PET]). The survey contained 31\u00a0questions in German language (yes\/no questions, multiple choice [MC] questions, multiple select [MS] questions, and free-text entry options). The survey was distributed twice via the DEGRO member mailing list.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During the survey period (May\u00a022\u2013August\u00a07, 2023) a\u00a0total of 156 RadOncs (13% of respondents) answered the survey. Among these, 59% reported access to diagnostic PET\/CT within their organization\/clinic and 24% have fixed timeslots for their patients. 37% of survey participants can perform RT-PET and 29% have the option of providing a\u00a0dedicated RT technician for planning PET. Besides [<jats:sup>18<\/jats:sup>F]-fluorodeoxyglucose (FDG; mainly used in lung cancer: 95%), diagnostic prostate-specific membrane antigen (PSMA)-PET\/CT for RT of prostate cancer is routinely used by 44% of participants (by 64% in salvage RT). Use of amino acid PET in brain tumors and somatostatin receptor PET in meningioma is low (19\u00a0and 25%, respectively). Scans are reimbursed through private (75%) or compulsory (55%) health insurance or as part of indications approved by the German Joint Federal Committee (<jats:italic>Gemeinsamer Bundesausschuss<\/jats:italic>; 59%). 98% of RadOncs agree that PET impacts target volume definition and 62% think that it impacts RT dose prescription.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This is the first nationwide survey on the role of PET\/CT for RT planning among RadOncs in Germany. We find high acceptance of PET results for treatment decisions and target volume definition. Planning PET comes with logistic challenges for different healthcare settings (e.g., private practices vs. university hospitals). The decision to request PET\/CT is often based on the possibility of reimbursement.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>PET\/CT has become an important tool for RadOncs, with several indications. However, access is still limited at several sites, especially for dedicated RT-PET. This study aims to improve interdisciplinary cooperation and adequate implementation of current guidelines for the treatment of various tumor entities.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00066-024-02260-4","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T09:12:22Z","timestamp":1723194742000},"page":"931-941","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Implementation of PET\/CT in radiation oncology\u2014a\u00a0patterns-of-care analysis of the German Society of Nuclear Medicine and the German Society of Radiation Oncology"],"prefix":"10.1007","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0361-728X","authenticated-orcid":false,"given":"Simone","family":"Wegen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Nestle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos","family":"Zamboglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon K. B.","family":"Spohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils Henrik","family":"Nicolay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena M.","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan A.","family":"Koerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"La Foug\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Fokas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Kobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chukwuka","family":"Eze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca-Ligia","family":"Grosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Holzgreve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina-Sophie","family":"Schmidt-Hegemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"key":"2260_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00066-021-01812-2","volume":"197","author":"C Lapa","year":"2021","unstructured":"Lapa\u00a0C, Nestle\u00a0U, Albert\u00a0NL, Baues\u00a0C, Beer\u00a0A, Buck\u00a0A et\u00a0al (2021) Value of PET imaging for radiation therapy. Strahlenther Onkol 197:1\u201323. https:\/\/doi.org\/10.1007\/s00066-021-01812-2","journal-title":"Strahlenther Onkol"},{"key":"2260_CR2","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1055\/a-1525-7029","volume":"60","author":"C Lapa","year":"2021","unstructured":"Lapa\u00a0C, Nestle\u00a0U, Albert\u00a0NL, Baues\u00a0C, Beer\u00a0A, Buck\u00a0A et\u00a0al (2021) Value of PET imaging for radiation therapy. Nuklearmedizin 60:326\u2013343. https:\/\/doi.org\/10.1055\/a-1525-7029","journal-title":"Nuklearmedizin"},{"key":"2260_CR3","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1470-2045(20)30013-9","volume":"21","author":"U Nestle","year":"2020","unstructured":"Nestle\u00a0U, Schimek-Jasch\u00a0T, Kremp\u00a0S, Schaefer-Schuler\u00a0A, Mix\u00a0M, Kusters\u00a0A et\u00a0al (2020) Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a\u00a0multicentre, open-label, randomised, controlled trial. Lancet Oncol 21:581\u2013592. https:\/\/doi.org\/10.1016\/S1470-2045(20)30013-9","journal-title":"Lancet Oncol"},{"key":"2260_CR4","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler\u00a0WP, Calais\u00a0J, Eiber\u00a0M, Flavell\u00a0RR, Mishoe\u00a0A, Feng\u00a0FY et\u00a0al (2019) Assessment of 68ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a\u00a0prospective single-arm clinical trial. JAMA Oncol 5:856\u2013863. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0096","journal-title":"JAMA Oncol"},{"key":"2260_CR5","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman\u00a0MS, Lawrentschuk\u00a0N, Francis\u00a0RJ, Tang\u00a0C, Vela\u00a0I, Thomas\u00a0P et\u00a0al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a\u00a0prospective, randomised, multicentre study. Lancet 395:1208\u20131216. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7","journal-title":"Lancet"},{"key":"2260_CR6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00066-005-1422-7","volume":"181","author":"AL Grosu","year":"2005","unstructured":"Grosu\u00a0AL, Piert\u00a0M, Weber\u00a0WA, Jeremic\u00a0B, Picchio\u00a0M, Schratzenstaller\u00a0U et\u00a0al (2005) Positron emission tomography for radiation treatment planning. Strahlenther Onkol 181:483\u2013499. https:\/\/doi.org\/10.1007\/s00066-005-1422-7","journal-title":"Strahlenther Onkol"},{"key":"2260_CR7","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.2967\/jnumed.108.055780","volume":"50","author":"EC Ford","year":"2009","unstructured":"Ford\u00a0EC, Herman\u00a0J, Yorke\u00a0E, Wahl\u00a0RL (2009) 18F-FDG PET\/CT for image-guided and intensity-modulated radiotherapy. J\u00a0Nucl Med 50:1655\u20131665. https:\/\/doi.org\/10.2967\/jnumed.108.055780","journal-title":"J Nucl Med"},{"key":"2260_CR8","series-title":"IAEA-TECDOC","volume-title":"The role of PET\/CT in radiation treatment planning for cancer patient treatment","author":"International Atomic Energy Agency","year":"2008","unstructured":"International Atomic Energy Agency (2008) The role of PET\/CT in radiation treatment planning for cancer patient treatment. IAEA-TECDOC, vol 1603. IAEA, Vienna"},{"key":"2260_CR9","unstructured":"Richtlinie des Gemeinsamen Bundesausschusses zu Untersuchungs- und Behandlungsmethoden der vertrags\u00e4rztlichen Versorgung (Richtlinie Methoden vertrags\u00e4rztliche Versorgung) in der Fassung vom 17.\u00a0Januar 2006 ver\u00f6ffentlicht im Bundesanzeiger Nr.\u00a048 (S.\u00a01523) vom 9.\u00a0M\u00e4rz 2006 in Kraft getreten am 1.\u00a0April 2006 zuletzt ge\u00e4ndert am 20.\u00a0Oktober 2022 ver\u00f6ffentlicht im Bundesanzeiger (BAnz AT 13 Jan 2023 B3) in Kraft getreten am 14.\u00a0Januar 2023."},{"key":"2260_CR10","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1186\/s12885-016-2806-z","volume":"16","author":"O Oehlke","year":"2016","unstructured":"Oehlke\u00a0O, Mix\u00a0M, Graf\u00a0E, Schimek-Jasch\u00a0T, Nestle\u00a0U, Gotz\u00a0I et\u00a0al (2016) Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA)\u2014protocol of a\u00a0randomized phase\u00a0II trial (NOA 10\/ARO 2013-1). BMC Cancer 16:769. https:\/\/doi.org\/10.1186\/s12885-016-2806-z","journal-title":"BMC Cancer"},{"key":"2260_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.radonc.2018.08.019","volume":"130","author":"I Popp","year":"2019","unstructured":"Popp\u00a0I, Bott\u00a0S, Mix\u00a0M, Oehlke\u00a0O, Schimek-Jasch\u00a0T, Nieder\u00a0C et\u00a0al (2019) Diffusion-weighted MRI and ADC versus FET-PET and GdT1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma. Radiother Oncol 130:121\u2013131. https:\/\/doi.org\/10.1016\/j.radonc.2018.08.019","journal-title":"Radiother Oncol"},{"key":"2260_CR12","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","volume":"390","author":"P Borchmann","year":"2017","unstructured":"Borchmann\u00a0P, Goergen\u00a0H, Kobe\u00a0C, Lohri\u00a0A, Greil\u00a0R, Eichenauer\u00a0DA et\u00a0al (2017) PET-guided treatment in patients with advanced-stage hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase\u00a03\u00a0trial by the German hodgkin study group. Lancet 390:2790\u20132802. https:\/\/doi.org\/10.1016\/S0140-6736(17)32134-7","journal-title":"Lancet"},{"key":"2260_CR13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","volume":"22","author":"P Borchmann","year":"2021","unstructured":"Borchmann\u00a0P, Plutschow\u00a0A, Kobe\u00a0C, Greil\u00a0R, Meissner\u00a0J, Topp\u00a0MS et\u00a0al (2021) PET-guided omission of radiotherapy in early-stage unfavourable hodgkin lymphoma (GHSG HD17): a\u00a0multicentre, open-label, randomised, phase\u00a03\u00a0trial. Lancet Oncol 22:223\u2013234. https:\/\/doi.org\/10.1016\/S1470-2045(20)30601-X","journal-title":"Lancet Oncol"},{"key":"2260_CR14","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","volume":"89","author":"L Specht","year":"2014","unstructured":"Specht\u00a0L, Yahalom\u00a0J, Illidge\u00a0T, Berthelsen\u00a0AK, Constine\u00a0LS, Eich\u00a0HT et\u00a0al (2014) Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 89:854\u2013862. https:\/\/doi.org\/10.1016\/j.ijrobp.2013.05.005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2260_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06431-w","author":"J Ferdinandus","year":"2023","unstructured":"Ferdinandus\u00a0J, van Heek\u00a0L, Roth\u00a0K, Dietlein\u00a0M, Eich\u00a0HT, Baues\u00a0C et\u00a0al (2023) Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage hodgkin\u2019s lymphoma: an analysis of the randomized phase\u00a0III HD18 trial by the German hodgkin study group. Eur J Nucl Med Mol Imaging. https:\/\/doi.org\/10.1007\/s00259-023-06431-w","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2260_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.014","author":"J Ferdinandus","year":"2023","unstructured":"Ferdinandus\u00a0J, Muller\u00a0H, Damaschin\u00a0C, Jacob\u00a0AS, Meissner\u00a0J, Krasniqi\u00a0F et\u00a0al (2023) Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced stage hodgkin lymphoma: results from the randomized international GHSG HD18 trial. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.014","journal-title":"Ann Oncol"},{"key":"2260_CR17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ijrobp.2006.02.047","volume":"66","author":"AL Grosu","year":"2006","unstructured":"Grosu\u00a0AL, Weber\u00a0WA, Astner\u00a0ST, Adam\u00a0M, Krause\u00a0BJ, Schwaiger\u00a0M et\u00a0al (2006) 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 66:339\u2013344. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.02.047","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2260_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13014-021-01811-8","volume":"16","author":"MME Vogel","year":"2021","unstructured":"Vogel\u00a0MME, Dewes\u00a0S, Sage\u00a0EK, Devecka\u00a0M, Gschwend\u00a0JE, Eiber\u00a0M et\u00a0al (2021) A\u00a0survey among German-speaking radiation oncologists on PET-based radiotherapy of prostate cancer. Radiat Oncol 16:82. https:\/\/doi.org\/10.1186\/s13014-021-01811-8","journal-title":"Radiat Oncol"},{"key":"2260_CR19","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1007\/s00066-018-1291-5","volume":"194","author":"T Frenzel","year":"2018","unstructured":"Frenzel\u00a0T, Tienken\u00a0M, Abel\u00a0M, Berliner\u00a0C, Klutmann\u00a0S, Beyersdorff\u00a0D et\u00a0al (2018) The impact of [(68)Ga]PSMA I&T PET\/CT on radiotherapy planning in patients with prostate cancer. Strahlenther Onkol 194:646\u2013654. https:\/\/doi.org\/10.1007\/s00066-018-1291-5","journal-title":"Strahlenther Onkol"},{"key":"2260_CR20","doi-asserted-by":"publisher","first-page":"929444","DOI":"10.3389\/fonc.2022.929444","volume":"12","author":"M Alberto","year":"2022","unstructured":"Alberto\u00a0M, Yim\u00a0A, Papa\u00a0N, Siva\u00a0S, Ischia\u00a0J, Touijer\u00a0K et\u00a0al (2022) Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer. Front Oncol 12:929444. https:\/\/doi.org\/10.3389\/fonc.2022.929444","journal-title":"Front Oncol"},{"key":"2260_CR21","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2967\/jnumed.118.220855","volume":"60","author":"NS Schmidt-Hegemann","year":"2019","unstructured":"Schmidt-Hegemann\u00a0NS, Eze\u00a0C, Li\u00a0M, Rogowski\u00a0P, Schaefer\u00a0C, Stief\u00a0C et\u00a0al (2019) Impact of (68)ga-PSMA PET\/CT on the radiotherapeutic approach to prostate cancer in comparison to CT: a\u00a0retrospective analysis. J\u00a0Nucl Med 60:963\u2013970. https:\/\/doi.org\/10.2967\/jnumed.118.220855","journal-title":"J Nucl Med"},{"key":"2260_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13014-018-0983-4","volume":"13","author":"NS Schmidt-Hegemann","year":"2018","unstructured":"Schmidt-Hegemann\u00a0NS, Fendler\u00a0WP, Ilhan\u00a0H, Herlemann\u00a0A, Buchner\u00a0A, Stief\u00a0C et\u00a0al (2018) Outcome after PSMA PET\/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy. Radiat Oncol 13:37. https:\/\/doi.org\/10.1186\/s13014-018-0983-4","journal-title":"Radiat Oncol"},{"key":"2260_CR23","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1007\/s00259-023-06332-y","volume":"50","author":"A Holzgreve","year":"2023","unstructured":"Holzgreve\u00a0A, Unterrainer\u00a0M, Calais\u00a0J, Adams\u00a0T, Oprea-Lager\u00a0DE, Goffin\u00a0K et\u00a0al (2023) Is PSMA PET\/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial. Eur J Nucl Med Mol Imaging 50:3750\u20133754. https:\/\/doi.org\/10.1007\/s00259-023-06332-y","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2260_CR24","doi-asserted-by":"publisher","first-page":"e2314748","DOI":"10.1001\/jamanetworkopen.2023.14748","volume":"6","author":"C Zamboglou","year":"2023","unstructured":"Zamboglou\u00a0C, Peeken\u00a0JC, Janbain\u00a0A, Katsahian\u00a0S, Strouthos\u00a0I, Ferentinos\u00a0K et\u00a0al (2023) Development and validation of a\u00a0multi-institutional nomogram of outcomes for PSMA-PET-based salvage radiotherapy for recurrent prostate cancer. JAMA Netw Open 6:e2314748. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.14748","journal-title":"JAMA Netw Open"},{"key":"2260_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225795","author":"C Zamboglou","year":"2021","unstructured":"Zamboglou\u00a0C, Spohn\u00a0SKB, Adebahr\u00a0S, Huber\u00a0M, Kirste\u00a0S, Sprave\u00a0T et\u00a0al (2021) PSMA-PET\/MRI-based focal dose escalation in patients with primary prostate cancer treated with stereotactic body radiation therapy (hypofocal-SBRT): study protocol of a\u00a0randomized, multicentric phase\u00a0III trial. Cancers. https:\/\/doi.org\/10.3390\/cancers13225795","journal-title":"Cancers"},{"key":"2260_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-023-02117-2","author":"S Wegen","year":"2023","unstructured":"Wegen\u00a0S, Weindler\u00a0J, Voltin\u00a0CA, van Heek\u00a0L, Schomacker\u00a0K, Fischer\u00a0T et\u00a0al (2023) Dual-tracer PET\/CT protocol with [(18)F]FDG and [(68)Ga]Ga-FAPI-46 outperforms single-tracer PET\/CT with [(18)F]FDG in different cancer types, resulting in larger functional and gross tumor volume. Strahlenther Onkol. https:\/\/doi.org\/10.1007\/s00066-023-02117-2","journal-title":"Strahlenther Onkol"},{"key":"2260_CR27","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1007\/s00259-020-04859-y","volume":"47","author":"M Syed","year":"2020","unstructured":"Syed\u00a0M, Flechsig\u00a0P, Liermann\u00a0J, Windisch\u00a0P, Staudinger\u00a0F, Akbaba\u00a0S et\u00a0al (2020) Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers. Eur J Nucl Med Mol Imaging 47:2836\u20132845. https:\/\/doi.org\/10.1007\/s00259-020-04859-y","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2260_CR28","doi-asserted-by":"publisher","first-page":"16261","DOI":"10.1038\/s41598-022-20447-6","volume":"12","author":"N Guberina","year":"2022","unstructured":"Guberina\u00a0N, Kessler\u00a0L, Pottgen\u00a0C, Guberina\u00a0M, Metzenmacher\u00a0M, Herrmann\u00a0K et\u00a0al (2022) (68)Ga]FAPI-PET\/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidcystic carcinomas. Sci Rep 12:16261. https:\/\/doi.org\/10.1038\/s41598-022-20447-6","journal-title":"Sci Rep"},{"key":"2260_CR29","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.2967\/jnumed.123.266046","volume":"64","author":"SA Koerber","year":"2023","unstructured":"Koerber\u00a0SA, Rohrich\u00a0M, Walkenbach\u00a0L, Liermann\u00a0J, Choyke\u00a0PL, Fink\u00a0C et\u00a0al (2023) Impact of (68)ga-FAPI PET\/CT on staging and oncologic management in a\u00a0cohort of 226 patients with various cancers. J\u00a0Nucl Med 64:1712\u20131720. https:\/\/doi.org\/10.2967\/jnumed.123.266046","journal-title":"J Nucl Med"},{"key":"2260_CR30","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1007\/s11307-022-01749-7","volume":"24","author":"S Wegen","year":"2022","unstructured":"Wegen\u00a0S, van Heek\u00a0L, Linde\u00a0P, Claus\u00a0K, Akuamoa-Boateng\u00a0D, Baues\u00a0C et\u00a0al (2022) Head-to-head comparison of [(68) ga]ga-FAPI-46-PET\/CT and [(18)F]F-FDG-PET\/CT for radiotherapy planning in head and neck cancer. Mol Imaging Biol 24:986\u2013994. https:\/\/doi.org\/10.1007\/s11307-022-01749-7","journal-title":"Mol Imaging Biol"},{"key":"2260_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040796","author":"J Liermann","year":"2021","unstructured":"Liermann\u00a0J, Syed\u00a0M, Ben-Josef\u00a0E, Schubert\u00a0K, Schlampp\u00a0I, Sprengel\u00a0SD et\u00a0al (2021) Impact of FAPI-PET\/CT on target volume definition in radiation therapy of locally recurrent pancreatic cancer. Cancers. https:\/\/doi.org\/10.3390\/cancers13040796","journal-title":"Cancers"},{"key":"2260_CR32","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.radonc.2010.07.020","volume":"96","author":"M Coffey","year":"2010","unstructured":"Coffey\u00a0M, Vaandering\u00a0A (2010) Patient setup for PET\/CT acquisition in radiotherapy planning. Radiother Oncol 96:298\u2013301. https:\/\/doi.org\/10.1016\/j.radonc.2010.07.020","journal-title":"Radiother Oncol"},{"key":"2260_CR33","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.ijrobp.2008.09.041","volume":"73","author":"AB Hwang","year":"2009","unstructured":"Hwang\u00a0AB, Bacharach\u00a0SL, Yom\u00a0SS, Weinberg\u00a0VK, Quivey\u00a0JM, Franc\u00a0BL et\u00a0al (2009) Can positron emission tomography (PET) or PET\/computed tomography (CT) acquired in a\u00a0nontreatment position be accurately registered to a\u00a0head-and-neck radiotherapy planning CT? Int J Radiat Oncol Biol Phys 73:578\u2013584. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.09.041","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2260_CR34","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/RLU.0000000000004505","volume":"48","author":"S Wegen","year":"2023","unstructured":"Wegen\u00a0S, Roth\u00a0KS, Weindler\u00a0J, Claus\u00a0K, Linde\u00a0P, Trommer\u00a0M et\u00a0al (2023) First clinical experience with [68ga]ga-FAPI-46-PET\/CT versus [18F]F-FDG PET\/CT for nodal staging in cervical cancer. Clin Nucl Med 48:150\u2013155. https:\/\/doi.org\/10.1097\/RLU.0000000000004505","journal-title":"Clin Nucl Med"},{"key":"2260_CR35","first-page":"980","volume":"45","author":"PA Heeren","year":"2004","unstructured":"Heeren\u00a0PA, Jager\u00a0PL, Bongaerts\u00a0F, van Dullemen\u00a0H, Sluiter\u00a0W, Plukker\u00a0JT (2004) Detection of distant metastases in esophageal cancer with (18)F-FDG PET. J\u00a0Nucl Med 45:980\u2013987","journal-title":"J Nucl Med"},{"key":"2260_CR36","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2214\/AJR.17.18301","volume":"209","author":"R Goel","year":"2017","unstructured":"Goel\u00a0R, Moore\u00a0W, Sumer\u00a0B, Khan\u00a0S, Sher\u00a0D, Subramaniam\u00a0RM (2017) Clinical practice in PET\/CT for the management of head and neck squamous cell cancer. AJR Am J Roentgenol 209:289\u2013303. https:\/\/doi.org\/10.2214\/AJR.17.18301","journal-title":"AJR Am J Roentgenol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02260-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-024-02260-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02260-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T18:03:35Z","timestamp":1730397815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-024-02260-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2260"],"URL":"https:\/\/doi.org\/10.1007\/s00066-024-02260-4","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,9]]},"assertion":[{"value":"25 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.M.\u00a0Unterrainer discloses personal fees (speaker honorary and\/or advisory boards fees) from Astellas Pharma Inc., Novartis Radiopharmaceuticals, Telix-Pharmaceuticals, and ABX Radiopharmaceuticals. LMU is supported by the Clinician Scientist Program of the LMU Munich. W.P.\u00a0Fendler reports fees from SOFIE Bioscience (research funding), Janssen (consultant, speaker), Calyx (consultant, image review), Bayer (consultant, speaker, research funding), Novartis (speaker, consultant), Telix (speaker), GE Healthcare (speaker), Eczac\u0131ba\u015f\u0131 Monrol (speaker), Abx (speaker), Amgen (speaker), and Urotrials (speaker) outside of the submitted work. S.\u00a0Wegen, U.\u00a0Nestle, C.\u00a0Zamboglou, S.K.B.\u00a0Spohn, N.H.\u00a0Nicolay, S.A.\u00a0Koerber, C.\u00a0La Foug\u00e8re, E.\u00a0Fokas, C.\u00a0Kobe, C.\u00a0Eze, A.-L.\u00a0Grosu, A.\u00a0Holzgreve, R.\u00a0Werner and N.-S.\u00a0Schmidt-Hegemann declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}